NervGen looking to use their technology to revolutionize nerve damage treatment

NervGen Pharma (CVE:NGEN) President and CEO Ernest Wong sat down with Steve Darling from Proactive Investors Vancouver to talk about the pharma company that has technology that hopes to regenerate nerve damage, that damage can be spinal cord or peripheral. Wong telling Proactive how the drug works and where it is in the pipeline and when NervGen hopes to get into a phase one clinical study.

This entry was posted in Regenerative Medicine, spinal cord injury research, Uncategorized and tagged , , . Bookmark the permalink.